A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
ConditionMalignant Tumors
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLaNova Medicines Limited
About this trial
This study is to assess the safety and tolerability, obtain Maximum Tolerated Dose (MTD) and/or the recommended phase 2 dose (RP2D) of LM-101 as a single agent or in combination in patients with advanced malignant tumors
Eligibility criteria
Qualifiers
Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
Aged ≥18 years old, male or female.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Life expectancy ≥ 3 months.
Disqualifiers
Subject has received prior investigational therapy directed at the same target therapy.
Subjects has participated in any other interventional clinical trial within 21 days prior to the first dosing of LM-101.
Subjects with anti-tumor treatment within 21 days prior to the first dosing of LM-101, including radiotherapy, chemotherapy, endocrine therapy, and immunotherapy, etc.
Any adverse event from prior anti-tumor therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
Trial design
Treatments tested in this trial
- LM101
- Toripalimab
- Rituximab
Treatment groups
139 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov